Targeting CXCR6 Disrupts β-Catenin Signaling and Enhances Sorafenib Response in Hepatocellular Carcinoma.

Cancers (Basel) · 2025 · PMC12691426 · PMID 41375019

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

trending toward significancep = 0.054so close (0.05 < p ≤ 0.1)

In the combination, SBI-457 attenuated sorafenib-induced β-catenin upregulation, trending toward significance ( p = 0.054; Figure 2 C).

also in 580 other papers

did not reach statistical significanceno p-value reported

Although differences were subtle and did not reach statistical significance, this trend supports a mechanism by which CXCR6 antagonism prevents sorafenib-induced β-catenin stabilization through maintenance of GSK3β activity. 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.